Subsequent Events

3 Months Ended

Mar. 31, 2022

Subsequent Events [Abstract]

Subsequent Events

12. Subsequent Events

Proposed Merger with GlaxoSmithKline

On April 12, 2022, the Company entered into a Merger Agreement as further described in Note 1.

For additional information regarding the Merger, please refer to the Merger Agreement, which was filed with the SEC on April 13, 2022, as an exhibit to a Current Report on Form 8-K.

Common Stock Issuances

In April 2022, the Company issued 212,477 shares of common stock for the exercise of Series B Warrants for proceeds of $2.8 million prior to their expiration on April 10, 2022.

In April 2022, the Company issued 7,575 shares of common stock for the cash exercise of Series A Warrants for proceeds of $0.1 million. In addition, 373,606 shares of common stock were issued for the cashless exercise of Series A Warrants.

In April 2022, the Company issued 25,282 shares of common stock in connection with the exercise of stock options under pre-established non-discretionary sales plans and by a former employee for proceeds of $0.3 million.